Among diabetic patients, there were no differences in death, MI or cerebrovascular accident between PES and CABG groups in either those treated with insulin (182) or those treated with oral hypoglycemics (270).
The authors cautioned that the 1-year results may not yet reflect the true long-term differences between CABG and PES treatments of diabetic patients.
Dr. Dauerman reported significant financial relationships with Abbott Laboratories and Medtronic Inc.